| Literature DB >> 32077346 |
Corrado Pelaia1, Alessandro Vatrella2, Angela Sciacqua3, Rosa Terracciano4, Girolamo Pelaia1.
Abstract
Introduction: The p38 serine-threonine kinases are members of the large family of mitogen-activated protein kinases (MAPK). In particular, p38 MAPK subgroup includes four isoforms (α, β, γ, δ), among which p38α and p38β are mainly involved in inflammatory disorders. Indeed, by activating key transcription factors and by inducing the expression of several cytokines and chemokines, p38α plays a central role in the pathobiology of chronic obstructive pulmonary disease (COPD).Areas covered: This concise review focuses on the contribution of p38 MAPK to development, maintenance, and amplification of chronic lung inflammation in COPD. Moreover, we discuss the potential role of p38 MAPK as suitable target for perspective therapeutic approaches under evaluation as potential new COPD treatments. In this regard, an extensive literature search has been conducted throughout PubMed source (1990-2020).Expert opinion: Despite some promising preclinical data, so far the results of clinical trials evaluating p38 MAPK inhibitors have been quite disappointing, thus suggesting a cautious judgment about the future perspectives of these drugs for COPD therapy.Entities:
Keywords: COPD; lung inflammation; p38 MAPK; p38 inhibitors
Mesh:
Substances:
Year: 2020 PMID: 32077346 DOI: 10.1080/17476348.2020.1732821
Source DB: PubMed Journal: Expert Rev Respir Med ISSN: 1747-6348 Impact factor: 3.772